Literature DB >> 476055

Dialdehydes derived from adenine nucleosides as substrates and inhibitors of adenosine aminohydrolase.

A J Grant, L M Lerner.   

Abstract

A series of nucleoside dialdehydes have been obtained as powders after treatment of various adenine nucleosides with paraperiodic acid. Thus, oxidation gave dialdehydes derived from adenosine (1), 9-alpha-D-mannopyranosyladenine (2), 9-(5-deoxy-alpha-D-arabinofuranosyl)adenine (3), 9-alpha-L-rhamnopyranosyladenine (4), 9-beta-L-fucopyranosyladenine (5), 9-beta-D-fucopyranosyladenine (6), 9-alpha-D-arabinopyranosyladenine (7), 9-beta-D-ribopyranosyladenine (8), and 9-(5-deoxy-beta-D-erythro-pent-4-enofuranosyl)adenine (9). Nucleoside dialdehydes 1-3 and 6-8 were weak substrates for adenosine aminohydrolase from calf intestinal mucosa. Dialdehyde 8 had the strongest affinity, but 1 had the highest Vmax. All of the dialdehydes except 5 were inhibitors of the enzyme. The best inhibitors were 9 (Ki = 4 microM) and 4 (ki = 28 microM), and neither were substrates. The inhibitors did not exhibit time-dependent inhibition and did not appear to form covalent bonds with the protein. The data strongly suggest that the active form of the dialdehydes is as the open-chain dihydrates. The alcohol obtained by reduction of 9 (compound 10) was the strongest inhibitor (Ki = 0.9 microM among the related alcohols and the nucleoside dialdehydes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 476055     DOI: 10.1021/bi00580a025

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  2 in total

1.  Antiproliferative activity of purine nucleoside dialdehydes against leukemia L1210 in vitro.

Authors:  B Sheid; M Saggar; E Gaetjens; L M Lerner
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Amyotrophic lateral sclerosis-linked FUS/TLS alters stress granule assembly and dynamics.

Authors:  Desiree M Baron; Laura J Kaushansky; Catherine L Ward; Reddy Ranjith K Sama; Ru-Ju Chian; Kristin J Boggio; Alexandre J C Quaresma; Jeffrey A Nickerson; Daryl A Bosco
Journal:  Mol Neurodegener       Date:  2013-08-31       Impact factor: 14.195

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.